Status:
COMPLETED
TAVI PACER: A Two-step Risk Score for Prediction of Permanent Pacemaker Implantation After TAVI.
Lead Sponsor:
German Heart Institute
Conditions:
Pacemaker
TAVI
Eligibility:
All Genders
51-95 years
Brief Summary
The need for permanent pacemaker implantation (PPMI) remains one of the most frequent complications after transcatheter aortic valve implantation (TAVI). This study aimed to develop a novel, two-step ...
Eligibility Criteria
Inclusion
- Patients undergoing TAVI at Deutsches Herzzentrum der Charité between January 2019 and December 2020
Exclusion
- previous device implantation
- valve-in-valve procedure
- patients who had received an ALLEGRATM valve (NVT AG, Morges, Switzerland), a LOTUS EdgeTM valve (Boston, Scientific, Natick, Massachusetts), or a CENTERATM valve (Edwards Lifesciences, Irvine, California)
Key Trial Info
Start Date :
February 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 28 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06542380
Start Date
February 7 2022
End Date
June 28 2024
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Deutsches Herzzentrum der Charité
Mitte, State of Berlin, Germany, 10117